1.5166
Adlai Nortye Ltd Adr stock is traded at $1.5166, with a volume of 296.
It is up +1.11% in the last 24 hours and down -5.80% over the past month.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
See More
Previous Close:
$1.50
Open:
$1.4782
24h Volume:
296
Relative Volume:
0.02
Market Cap:
$57.93M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-0.6019
EPS:
-2.5197
Net Cash Flow:
-
1W Performance:
-7.52%
1M Performance:
-5.80%
6M Performance:
-37.84%
1Y Performance:
-58.28%
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Compare ANL with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ANL
Adlai Nortye Ltd Adr
|
1.5166 | 57.93M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Sep-04-24 | Initiated | H.C. Wainwright | Buy |
Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr Stock (ANL) Latest News
H.C. WAINWRIGHT CUTS ADLAI NORTYE STOCK RATING AFTER TRIAL RESULTS By Investing.com - Investing.com South Africa
H.C. WAINWRIGHT CUTS ADLAI NORTYE STOCK RATING AFTER TRIAL RESULTS - Investing.com
Adlai Nortye Discontinues Buparlisib Development After Phase III Trial Results - TipRanks
ANL stock touches 52-week low at $1.71 amid sharp annual decline - Investing.com India
ANL stock touches 52-week low at $1.71 amid sharp annual decline By Investing.com - Investing.com South Africa
ANL stock touches 52-week low at $1.85 amid sharp annual decline By Investing.com - Investing.com South Africa
ANL stock touches 52-week low at $1.85 amid sharp annual decline - Investing.com India
Adlai Nortye stock hits 52-week low at $1.85 amid sharp decline By Investing.com - Investing.com South Africa
Adlai Nortye stock hits 52-week low at $1.85 amid sharp decline - Investing.com India
Adlai Nortye Announces Change in Auditing Firm - TipRanks
Adlai Nortye Announces CFO Transition with Interim Appointment - TipRanks
Adlai Nortye IPO gives old Novartis cancer drug new life - BioPharma Dive
CRVO Stock Quote Price and Forecast - CNN
Adlai Nortye Ltd Adr Stock (ANL) Financials Data
There is no financial data for Adlai Nortye Ltd Adr (ANL). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):